Global Self-Monitoring Blood Glucose Device Market Report by Product, Application, End-User, Regions and Company Analysis 2024-2032

The Self-Monitoring Blood Glucose Device Market will be US$ 21.05 billion by 2032 from US$ 11.68 Billion in 2023, with a CAGR of 6.76% during 2024 to 2032.

Self-monitoring of blood glucose (SMBG) is essential to diabetes management. SMBG helps individuals with diabetes, and their healthcare professionals maintain a specific level of glycemic control and prevent hypoglycemia. SMBG collects blood glucose level data at various times to help maintain a more consistent glucose level through more accurate regimens. SMBG can also help adjust therapy regimens in response to blood glucose values and assist individuals in improving their dietary intake, physical activities, and insulin doses to enhance glycemic management daily.

People living with diabetes worldwide

• In 2021, 11.6% of Americans have diabetes, which includes 2 million with type 1 diabetes and 304,000 children with the condition.
• In 2023, In Canada, over 11.9 million individuals are currently affected by either diabetes or prediabetes.
• In the UK, there are over 4.3 million individuals who are living with diabetes.
• In 2022, Diabetes cases in Italy have increased from 2.9 million in 2010 to 3.9 million recently.
• In February 2023, approximately 1.2 million people in the Netherlands are affected by diabetes.
• The prevalence of diabetes among Chinese adults in 2020 is 11.2%, which amounts to approximately 141 million people, according to the NCBI.
• A 2023 ICMR study found that 101 million Indians have diabetes, a 36% increase from the 2021 estimate of 74.2 million.
• As of 2021, 11 million adults in Japan have diabetes, 11.8% of the total adult population.
• Over 73 million people in MENA have diabetes and it's expected to reach 135.7 million by 2045.
• In South Africa, there are over 4 million people who are living with diabetes.

China SMBG Market

China has the world's largest population of people with diabetes, with an estimated 141 million adults living with the disease. More than half of the adults currently living with diabetes in China are undiagnosed. The government has launched a 2017-2025 plan to control non-communicable diseases, including diabetes, and increase regular monitoring and self-management. Innovative technologies like digital health apps can further support self-management while decreasing disease burden. In 2023, Sinocare Inc. set up offline after-sales service outlets to explore new ways of preventing and controlling chronic diseases in China.

Self-Monitoring Blood Glucose Device Company Analysis

Abbott Laboratories, Medtronic, Dexcom, Inc., B. Braun Melsungen AG, DarioHealth Corp, Sanofi, Bionime Corporation, and Novo Nordisk are the major companies in the global self-monitoring blood glucose device market.

Self-Monitoring Blood Glucose Device Industry News

Dexcom G7, the latest CGM system, became available in Canada in October 2023. It features a subcutaneous sensor that transmits data via Bluetooth to a mobile app or receiver every five minutes.

• In June 2023, South Korea's Ministry of Food and Drug Safety has approved CareSens Air, the smallest and lightest continuous glucose monitoring (CGM) device developed by i-SENS, for use in the country. The device features a calibration mechanism and can be used continuously for 15 days.
• In March 2023- The U.S. FDA approved Abbott's FreeStyle Libre 2 and FreeStyle Libre 3 sensors for integration with automated insulin delivery systems.
• In Feb 2023- Apple significantly advanced non-invasive blood glucose monitoring for its Watch.
• In Feb 2023, Ascensia Diabetes Care Holdings AG, the inventor of the CONTOUR BGM system portfolio, globally partnered with SNAQ, a mobile application that presents nutritional understandings for people with diabetes.
• One Drop announced a study on their AI-powered blood glucose forecasting in July 2022.

Products - Market breakup in 3 viewpoints:

1. Test Strips

2. Lancets

3. Blood Glucose Meters

Application - Market breakup in 3 viewpoints:

1. Type 1 Diabetes

2. Type 2 Diabetes

3. Gestational Diabetes

End User - Market breakup in 4 viewpoints:

1. Hospital Pharmacies

2. Retail Pharmacies

3. Online Sales

4. Diabetes Clinics & Centers

Countries - Market breakup in 25 viewpoints:

1. North America

• 1.1 United States
• 1.2 Canada

2. Europe

• 2.1 France
• 2.2 Germany
• 2.3 Italy
• 2.4 Spain
• 2.5 United Kingdom
• 2.6 Belgium
• 2.7 Netherlands
• 2.8 Turkey

3. Asia Pacific

• 3.1 China
• 3.2 Japan
• 3.3 India
• 3.4 South Korea
• 3.5 Thailand
• 3.6 Malaysia
• 3.7 Indonesia
• 3.8 New Zealand
• 3.9 Australia

4. Latin America

• 4.1 Brazil
• 4.2 Mexico
• 4.3 Argentina

5. Middle East & Africa

• 5.1 Saudi Arabia
• 5.2 United Arab Emirates
• 5.3 South Africa

All the Key players have been covered from 3 Viewpoints:

• Overview
• Recent Development
• Revenue Analysis

Company Analysis:

1. Abbott Laboratories

2. Medtronic

3. Dexcom, Inc.

4. B. Braun Melsungen AG,

5. DarioHealth Corp,

6. Sanofi

7. Bionime Corporation

8. Novo Nordisk